2025 Q4 -tulosraportti
Vain PDF
36 päivää sitten
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 654 | - | - | ||
| 372 | - | - | ||
| 6 745 | - | - | ||
| 4 755 | - | - | ||
| 167 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 155 495 | 155 495 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 155 495 | 155 495 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 27.5.2025 | ||
2024 Q4 -tulosraportti 12.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·10 t sittenNice with a price drop. I'm indeed ready to buy and naturally want a discount.
·10 t sittenIf the latest news had come on good days, they should have been worth close to a doubling, at least a bottom of 3 kroner.- ·1 päivä sittenIt seems that many have not opened their eyes to this gem. The company provides a number of hints worth noting: JPM: - "Industry people from all over the world meet in the city to discuss business" - " We discuss our programs with potential licensees, follow up on previous conversations, and meet 1-to-1 with partners for focused conversations." - "It has not only validated our technology platform but also opened doors to new connections and increased interest across the entire portfolio." - Swedish version: "Emilsson testifies to an increased interest in Sprint Bioscience's early assets and highlights how the company's proven ability to deliver high-quality preclinical programs has served as a quality stamp, which facilitates new contacts and increases interest in the entire portfolio." - “We have had an intensive and rewarding week of meetings with both investors and potential partners." - "CEO Johan Emilsson reports an increased interest in early drug programs. " - "The agreement made in 2025 regarding one of programs has served as a strong seal of approval, not only validating the company's technology platform but also opening doors to new contacts and increasing interest in the entire portfolio."·1 päivä sittenOnly partially agree with you. One should take AI with a pinch of salt, but it is a useful tool for analyzing information. And then comes the clue. One must know what to feed in. One question is not enough. If you spend time and preparation, then it's quite good (remember, they screen the net for information in a fraction of the time compared to what you can do yourself)
·1 päivä sittenAnother value-creating press release - this time the DCPS program. Good momentum in their pipeline right now, which already had many interested parties at JP Morgan's event in January. "During the JPM-week, we noticed a significantly increased, more concrete interest in the entire portfolio." Concrete interest in the entire portfolio should also imply that one or another player is evaluating the entire company. An exciting future is an understatement!·1 päivä sittenI have noted that they are actively working towards investor communities. It seems they are trying to highlight the values that lie within the company (to drive up the price in an acquisition).- ·2 päivää sittenChatGPT: Assumptions Current market cap: ~200M SEK Number of shares: approx. 54M (free float and total adjusted) Program: VRK1, preclinical proof-of-concept Royalty: 8% in the scenarios, if market potential is realized Risk adjustment: typical probabilities for preclinical program (~5%) Scenario 1: Bear case – modest deal, limited upside Assumptions: Upfront: $40M (~425M SEK) Total deal value: $500M VRK2 biomarker only relevant in glioblastoma (~$500M peak sales) Risk adjustment: 5% chance of commercial success Result: Risk-adjusted value of VRK1: 25M USD (~265M SEK) Total value Sprint: ~465M SEK Share price estimate: ~8.6 SEK per share (from today's ~3.7 SEK) Scenario 2: Base case – solid deal, VRK1 relevant in several indications Assumptions: Upfront: $80M (~850M SEK) Total deal value: $900M VRK2 biomarker relevant in glioblastoma + 1–2 other cancer types (~$1.5B peak sales) Risk adjustment: 5% chance of commercial success Result: Risk-adjusted VRK1 value: 60M USD (~650M SEK) Total value Sprint: ~850–900M SEK Share price estimate: ~16–17 SEK per share Scenario 3: Bull case – first-in-class blockbuster, broad biomarker, competition for asset Assumptions: Upfront: $120M (~1,275M SEK) Total deal value: $1.3B VRK2 biomarker relevant in many cancer types (~$3B peak sales) Risk adjustment: 5% chance of commercial success Possibility for multiple partner agreements with other programs Result: Risk-adjusted VRK1 value: 150M USD (~1.6B SEK) Total value Sprint: 1.8–2B SEK Share price estimate: ~33–37 SEK per share Summary – risk vs upside Scenario Risk-adjusted VRK1 value Total Sprint value Estimated share price Bear 265M SEK 465M SEK 8.6 SEK Base 650M SEK 850–900M SEK 16–17 SEK Bull 1.6B SEK 1.8–2B SEK 33–37 SEK Key points VRK1 is the key driver for the value now. Partner deal + biomarker data can lead to a large share price reaction. The breadth of VRK2 loss in cancer types determines the upside. Preclinical risk is high, so downside must always be considered.
·2 päivää sitten · Muokattu🚀🚀🚀 Sprint Bioscience came with an update now that I believe strengthens the case quite a bit. They report positive preclinical results in the VRK1 program, which shows that their candidates actually work against the target as they hoped. VRK1 is an exciting target in cancer, especially related to cell growth and DNA repair, so this is not just any project. What makes this extra interesting is that the program was previously returned from a partner, which created some uncertainty. Now Sprint shows that the value is still there, and that they are able to develop the project further on their own. For me, it indicates that this can still become an important part of the pipeline. Sprint's model is about developing early projects and then licensing them out. Such positive data is exactly what is needed to attract new partners. Therefore, I think this is not just a research update, but a step closer to a potential agreement. As I see it, VRK1 again appears as a real trigger going forward. If they manage to land a new partner based on these results, it could become very interesting for the stock. Approx 39 million free shares outside top 15. good luck,- upcoming presentation‼️ Analysis performed by redeye: https://www.redeye.se/research/1148578/sprint-bioscience-q4-review-promising-development?utm_source=MFN&utm_medium=pmcour Do your own assessments!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
36 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·10 t sittenNice with a price drop. I'm indeed ready to buy and naturally want a discount.·10 t sittenIf the latest news had come on good days, they should have been worth close to a doubling, at least a bottom of 3 kroner.
- ·1 päivä sittenIt seems that many have not opened their eyes to this gem. The company provides a number of hints worth noting: JPM: - "Industry people from all over the world meet in the city to discuss business" - " We discuss our programs with potential licensees, follow up on previous conversations, and meet 1-to-1 with partners for focused conversations." - "It has not only validated our technology platform but also opened doors to new connections and increased interest across the entire portfolio." - Swedish version: "Emilsson testifies to an increased interest in Sprint Bioscience's early assets and highlights how the company's proven ability to deliver high-quality preclinical programs has served as a quality stamp, which facilitates new contacts and increases interest in the entire portfolio." - “We have had an intensive and rewarding week of meetings with both investors and potential partners." - "CEO Johan Emilsson reports an increased interest in early drug programs. " - "The agreement made in 2025 regarding one of programs has served as a strong seal of approval, not only validating the company's technology platform but also opening doors to new contacts and increasing interest in the entire portfolio."·1 päivä sittenOnly partially agree with you. One should take AI with a pinch of salt, but it is a useful tool for analyzing information. And then comes the clue. One must know what to feed in. One question is not enough. If you spend time and preparation, then it's quite good (remember, they screen the net for information in a fraction of the time compared to what you can do yourself)
- ·1 päivä sittenAnother value-creating press release - this time the DCPS program. Good momentum in their pipeline right now, which already had many interested parties at JP Morgan's event in January. "During the JPM-week, we noticed a significantly increased, more concrete interest in the entire portfolio." Concrete interest in the entire portfolio should also imply that one or another player is evaluating the entire company. An exciting future is an understatement!·1 päivä sittenI have noted that they are actively working towards investor communities. It seems they are trying to highlight the values that lie within the company (to drive up the price in an acquisition).
- ·2 päivää sittenChatGPT: Assumptions Current market cap: ~200M SEK Number of shares: approx. 54M (free float and total adjusted) Program: VRK1, preclinical proof-of-concept Royalty: 8% in the scenarios, if market potential is realized Risk adjustment: typical probabilities for preclinical program (~5%) Scenario 1: Bear case – modest deal, limited upside Assumptions: Upfront: $40M (~425M SEK) Total deal value: $500M VRK2 biomarker only relevant in glioblastoma (~$500M peak sales) Risk adjustment: 5% chance of commercial success Result: Risk-adjusted value of VRK1: 25M USD (~265M SEK) Total value Sprint: ~465M SEK Share price estimate: ~8.6 SEK per share (from today's ~3.7 SEK) Scenario 2: Base case – solid deal, VRK1 relevant in several indications Assumptions: Upfront: $80M (~850M SEK) Total deal value: $900M VRK2 biomarker relevant in glioblastoma + 1–2 other cancer types (~$1.5B peak sales) Risk adjustment: 5% chance of commercial success Result: Risk-adjusted VRK1 value: 60M USD (~650M SEK) Total value Sprint: ~850–900M SEK Share price estimate: ~16–17 SEK per share Scenario 3: Bull case – first-in-class blockbuster, broad biomarker, competition for asset Assumptions: Upfront: $120M (~1,275M SEK) Total deal value: $1.3B VRK2 biomarker relevant in many cancer types (~$3B peak sales) Risk adjustment: 5% chance of commercial success Possibility for multiple partner agreements with other programs Result: Risk-adjusted VRK1 value: 150M USD (~1.6B SEK) Total value Sprint: 1.8–2B SEK Share price estimate: ~33–37 SEK per share Summary – risk vs upside Scenario Risk-adjusted VRK1 value Total Sprint value Estimated share price Bear 265M SEK 465M SEK 8.6 SEK Base 650M SEK 850–900M SEK 16–17 SEK Bull 1.6B SEK 1.8–2B SEK 33–37 SEK Key points VRK1 is the key driver for the value now. Partner deal + biomarker data can lead to a large share price reaction. The breadth of VRK2 loss in cancer types determines the upside. Preclinical risk is high, so downside must always be considered.
- ·2 päivää sitten · Muokattu🚀🚀🚀 Sprint Bioscience came with an update now that I believe strengthens the case quite a bit. They report positive preclinical results in the VRK1 program, which shows that their candidates actually work against the target as they hoped. VRK1 is an exciting target in cancer, especially related to cell growth and DNA repair, so this is not just any project. What makes this extra interesting is that the program was previously returned from a partner, which created some uncertainty. Now Sprint shows that the value is still there, and that they are able to develop the project further on their own. For me, it indicates that this can still become an important part of the pipeline. Sprint's model is about developing early projects and then licensing them out. Such positive data is exactly what is needed to attract new partners. Therefore, I think this is not just a research update, but a step closer to a potential agreement. As I see it, VRK1 again appears as a real trigger going forward. If they manage to land a new partner based on these results, it could become very interesting for the stock. Approx 39 million free shares outside top 15. good luck,- upcoming presentation‼️ Analysis performed by redeye: https://www.redeye.se/research/1148578/sprint-bioscience-q4-review-promising-development?utm_source=MFN&utm_medium=pmcour Do your own assessments!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 654 | - | - | ||
| 372 | - | - | ||
| 6 745 | - | - | ||
| 4 755 | - | - | ||
| 167 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 155 495 | 155 495 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 155 495 | 155 495 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 27.5.2025 | ||
2024 Q4 -tulosraportti 12.2.2025 |
2025 Q4 -tulosraportti
Vain PDF
36 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 13.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 11.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 27.8.2025 | ||
2025 Q1 -tulosraportti 27.5.2025 | ||
2024 Q4 -tulosraportti 12.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·10 t sittenNice with a price drop. I'm indeed ready to buy and naturally want a discount.·10 t sittenIf the latest news had come on good days, they should have been worth close to a doubling, at least a bottom of 3 kroner.
- ·1 päivä sittenIt seems that many have not opened their eyes to this gem. The company provides a number of hints worth noting: JPM: - "Industry people from all over the world meet in the city to discuss business" - " We discuss our programs with potential licensees, follow up on previous conversations, and meet 1-to-1 with partners for focused conversations." - "It has not only validated our technology platform but also opened doors to new connections and increased interest across the entire portfolio." - Swedish version: "Emilsson testifies to an increased interest in Sprint Bioscience's early assets and highlights how the company's proven ability to deliver high-quality preclinical programs has served as a quality stamp, which facilitates new contacts and increases interest in the entire portfolio." - “We have had an intensive and rewarding week of meetings with both investors and potential partners." - "CEO Johan Emilsson reports an increased interest in early drug programs. " - "The agreement made in 2025 regarding one of programs has served as a strong seal of approval, not only validating the company's technology platform but also opening doors to new contacts and increasing interest in the entire portfolio."·1 päivä sittenOnly partially agree with you. One should take AI with a pinch of salt, but it is a useful tool for analyzing information. And then comes the clue. One must know what to feed in. One question is not enough. If you spend time and preparation, then it's quite good (remember, they screen the net for information in a fraction of the time compared to what you can do yourself)
- ·1 päivä sittenAnother value-creating press release - this time the DCPS program. Good momentum in their pipeline right now, which already had many interested parties at JP Morgan's event in January. "During the JPM-week, we noticed a significantly increased, more concrete interest in the entire portfolio." Concrete interest in the entire portfolio should also imply that one or another player is evaluating the entire company. An exciting future is an understatement!·1 päivä sittenI have noted that they are actively working towards investor communities. It seems they are trying to highlight the values that lie within the company (to drive up the price in an acquisition).
- ·2 päivää sittenChatGPT: Assumptions Current market cap: ~200M SEK Number of shares: approx. 54M (free float and total adjusted) Program: VRK1, preclinical proof-of-concept Royalty: 8% in the scenarios, if market potential is realized Risk adjustment: typical probabilities for preclinical program (~5%) Scenario 1: Bear case – modest deal, limited upside Assumptions: Upfront: $40M (~425M SEK) Total deal value: $500M VRK2 biomarker only relevant in glioblastoma (~$500M peak sales) Risk adjustment: 5% chance of commercial success Result: Risk-adjusted value of VRK1: 25M USD (~265M SEK) Total value Sprint: ~465M SEK Share price estimate: ~8.6 SEK per share (from today's ~3.7 SEK) Scenario 2: Base case – solid deal, VRK1 relevant in several indications Assumptions: Upfront: $80M (~850M SEK) Total deal value: $900M VRK2 biomarker relevant in glioblastoma + 1–2 other cancer types (~$1.5B peak sales) Risk adjustment: 5% chance of commercial success Result: Risk-adjusted VRK1 value: 60M USD (~650M SEK) Total value Sprint: ~850–900M SEK Share price estimate: ~16–17 SEK per share Scenario 3: Bull case – first-in-class blockbuster, broad biomarker, competition for asset Assumptions: Upfront: $120M (~1,275M SEK) Total deal value: $1.3B VRK2 biomarker relevant in many cancer types (~$3B peak sales) Risk adjustment: 5% chance of commercial success Possibility for multiple partner agreements with other programs Result: Risk-adjusted VRK1 value: 150M USD (~1.6B SEK) Total value Sprint: 1.8–2B SEK Share price estimate: ~33–37 SEK per share Summary – risk vs upside Scenario Risk-adjusted VRK1 value Total Sprint value Estimated share price Bear 265M SEK 465M SEK 8.6 SEK Base 650M SEK 850–900M SEK 16–17 SEK Bull 1.6B SEK 1.8–2B SEK 33–37 SEK Key points VRK1 is the key driver for the value now. Partner deal + biomarker data can lead to a large share price reaction. The breadth of VRK2 loss in cancer types determines the upside. Preclinical risk is high, so downside must always be considered.
- ·2 päivää sitten · Muokattu🚀🚀🚀 Sprint Bioscience came with an update now that I believe strengthens the case quite a bit. They report positive preclinical results in the VRK1 program, which shows that their candidates actually work against the target as they hoped. VRK1 is an exciting target in cancer, especially related to cell growth and DNA repair, so this is not just any project. What makes this extra interesting is that the program was previously returned from a partner, which created some uncertainty. Now Sprint shows that the value is still there, and that they are able to develop the project further on their own. For me, it indicates that this can still become an important part of the pipeline. Sprint's model is about developing early projects and then licensing them out. Such positive data is exactly what is needed to attract new partners. Therefore, I think this is not just a research update, but a step closer to a potential agreement. As I see it, VRK1 again appears as a real trigger going forward. If they manage to land a new partner based on these results, it could become very interesting for the stock. Approx 39 million free shares outside top 15. good luck,- upcoming presentation‼️ Analysis performed by redeye: https://www.redeye.se/research/1148578/sprint-bioscience-q4-review-promising-development?utm_source=MFN&utm_medium=pmcour Do your own assessments!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Sweden
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 654 | - | - | ||
| 372 | - | - | ||
| 6 745 | - | - | ||
| 4 755 | - | - | ||
| 167 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 155 495 | 155 495 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 155 495 | 155 495 | 0 | 0 |